Similar studies for GEO DataSets (Select 200126486) - GEO DataSets

Links from GEO DataSets

Items: 20

Select item 2001264861.

Genome-wide CRISPR-Cas9 screen identifies druggable synthetic lethality between LSD1 and MTORC1 in MLL-translocated AML

(Submitter supplied) Lysine Specific Demethylase 1 (LSD1 or KDM1A) is one of a number of epigenetic regulators which have recently emerged as candidate therapeutic targets in acute myeloid leukaemia (AML). Pharmacological inhibitors of LSD1 such as the tranylcypromine derivatives have already commenced evaluation in early phase clinical trials; however like all acute leukaemia therapies, it is unlikely that these inhibitors are effective as single agents. more...

Organism:: synthetic construct; Homo sapiens

Type:: Expression profiling by high throughput sequencing; Other

Platforms:: GPL18573 GPL16791 GPL19604
28 Samples

Download data: CSV, TXT

Series

Accession:: GSE126486

ID:: 200126486

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2001101782.

LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML

(Submitter supplied) Lsd1KO and ATRA treatment in Hoxa9/Meis1- and MN1-transformed myeloid progenitor cells LSD1 has emerged as a promising epigenetic target in the treatment of acute myeloid leukemia (AML). Inhibition of LSD1 has been shown to induce differentiation and facilitate the responsiveness of AML cells to all-trans retinoic acid. We used two murine AML models based on retroviral overexpression of Hoxa9/Meis1 (H9M) or MN1 to study the effect of Lsd1 knockout in AML. more...

Organism:: Mus musculus

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL21103 GPL17021
26 Samples

Download data: BED, TXT, XLSX

Series

Accession:: GSE110178

ID:: 200110178

PubMed Similar studies SRA Run Selector

Select item 2000347263.

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array; Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL10558 GPL10999
40 Samples

Download data: BED

Series

Accession:: GSE34726

ID:: 200034726

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000347254.

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia [ChIP-Seq]

(Submitter supplied) All-trans-retinoic acid (ATRA) has been successfully used in therapy of acute promyelocytic leukemia (APL), a cytogenetically distinct subtype of acute myeloid leukemia (AML) but the response of non-APL AML cases to ATRA-based treatment has been poor. Here we show that, via epigenetic reprogramming, inhibitors of LSD1/KDM1 demethylase including tranylcypromine (TCP) unlocked the ATRA-driven therapeutic response in non-APL AML. more...

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL10999
10 Samples

Download data: BED

Series

Accession:: GSE34725

ID:: 200034725

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2000346725.

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia [Illumina HumanHT-12 gene expression array]

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL10558
30 Samples

Download data: TXT

Series

Accession:: GSE34672

ID:: 200034672

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001577026.

Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of cyclin dependent kinase 6 in MLL-rearranged myeloid leukemia

(Submitter supplied) Acute myeloid leukemia (AML) with chromosomal rearrangements involving the H3K4 methyltransferase mixed-lineage leukemia (MLL) is an aggressive subtype with low overall survival. MLL rearrangements rapidly transform hematological stem and progenitor cell (HSPC) to leukemia stem cell (LSC). Bortezomib (Velcade) is used widely in hematological malignancies. However, it is still unknown whether bortezomib possesses anti-self-renewal and anti-leukemogenesis of LSC in AML with MLL rearrangements. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL11154
2 Samples

Download data: TXT, XLSX

Series

Accession:: GSE157702

ID:: 200157702

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 2000791107.

Zinc finger protein 521 overexpression is a feature of MLL-rearranged acute myeloid leukemia and contributes to the maintenance of myeloid differentiation block

(Submitter supplied) ZNF521 is a multiple zinc finger transcription factor previously identified because abundantly and selectively expressed in normal CD34+ hematopoietic stem and progenitor cells. From microarray datasets, aberrant expression of ZNF521 has been reported in both pediatric and adult acute myeloid leukemia (AML) patients with MLL gene rearrangements. However, a proper validation of microarray data is lacking, likewise ZNF521 contribution in MLL-rearranged AML is still uncertain. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
6 Samples

Download data: CEL

Series

Accession:: GSE79110

ID:: 200079110

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000875808.

A novel LSD1 inhibitor T-3775440 induces transdifferentiation in AML cell lines

(Submitter supplied) We describe the anti-leukemic activity and mechanism of action of T-3775440, a novel irreversible LSD1 inhibitor. Cell growth analysis of leukemia cell lines revealed that acute erythroleukemia (AEL) and acute megakaryoblastic leukemia cells (AMKL) are highly sensitive to this compound. T-3775440 treatment enforced transdifferentiation-like phenotypic change from erythroid/megakaryocytic lineages into granulomonocytic lineage. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL16699
12 Samples

Download data: TXT

Series

Accession:: GSE87580

ID:: 200087580

Select item 2001120749.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [anti-H3K9 ac, anti-H3K27, RCOR1, SPI1, and MLL4 ChIP-Seq]

(Submitter supplied) To determine whether changes in histone modifications directly correlate with changes in transcription, THP1 AML cells were treated with a potent and selective LSD1 inhibitor (OG86, 250nM) and then subjected to concomitant RNA sequencing (RNAseq) and ChIP sequencing (ChIPseq) for histone acetylation modifications, RCOR1, SPI1 and MLL4.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL18573
10 Samples

Download data: BW

Series

Accession:: GSE112074

ID:: 200112074

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20009077010.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [ATAC-Seq]

(Submitter supplied) To identify regions of genome accessibility influenced by LSD1 inhibition, THP1 AML cells were subjected to ATAC sequencing.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL18573
2 Samples

Download data: TXT

Series

Accession:: GSE90770

ID:: 200090770

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20009076911.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [anti-LSD1, MYB, and GFI1 ChIP-Seq]

(Submitter supplied) To identify genomic binding regions, THP1 AML cells were subjected to ChIP sequencing (ChIPseq) using anti-LSD1, MYB or GFI1 antibodies.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL18573
6 Samples

Download data: TXT

Series

Accession:: GSE90769

ID:: 200090769

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20006322212.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL16558 GPL18573 GPL16791
28 Samples

Download data: BW, TXT

Series

Accession:: GSE63222

ID:: 200063222

PubMed Full text in PMC Similar studies

Select item 20006321813.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [ChIP-Seq: histone modifications]

(Submitter supplied) To determine whether changes in histone modifications directly correlate with changes in transcription, THP1 AML cells were treated with a potent and selective LSD1 inhibitor (OG86) and then subjected to concomitant RNA sequencing (RNAseq) and ChIP sequencing (ChIPseq) for monomethyl-, dimethyl- and trimethyl histone H3 modifications.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL16791
6 Samples

Download data: TXT

Series

Accession:: GSE63218

ID:: 200063218

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20006321714.

Inhibitors of LSD1 target demethylase-independent activity to induce differentiation in acute myeloid leukemia [RNA-Seq experiments]

(Submitter supplied) To determine whether changes in histone modifications directly correlate with changes in transcription, THP1 AML cells were treated with a potent and selective LSD1 inhibitor (OG86) and then subjected to concomitant RNA sequencing (RNAseq) and ChIP sequencing (ChIPseq) for monomethyl-, dimethyl- and trimethyl histone H3 modifications.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL16558
4 Samples

Download data: TXT

Series

Accession:: GSE63217

ID:: 200063217

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20010082015.

Genetic deletion or small molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML

(Submitter supplied) The hematological malignancies classified as Mixed Lineage leukemias (MLL) harbor fusions of the MLL1 gene to partners that are members of transcriptional elongation complexes. MLL-rearranged leukemias are associated with extremely poor prognosis and response to conventional therapies and efforts to identify molecular targets are urgently needed. Using mouse models of MLL-rearranged acute myeloid leukemia (AML), here we show that genetic inactivation or small molecule inhibition of the protein arginine methyltransferase PRMT5 exhibit anti-tumoral activity in MLL-fusion protein driven transformation. more...

Organism:: Mus musculus

Type:: Expression profiling by high throughput sequencing

Platform:: GPL13112
6 Samples

Download data: TXT

Series

Accession:: GSE100820

ID:: 200100820

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20014475916.

Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition

(Submitter supplied) The interaction of Menin (MEN1) and MLL (MLL1, KMT2A) is a dependency and potential therapeutic opportunity against NPM1 mutant (NPM1mut) and MLL-rearranged (MLL-r) leukemias. Concomitant activating driver mutations in the gene encoding the tyrosine kinase FLT3 occur in both leukemias and are particularly common in the NPM1mut subtype. Transcriptional profiling upon pharmacological inhibition of the Menin-MLL complex revealed specific changes in gene expression with downregulation of the MEIS1 transcription factor and its transcriptional target gene FLT3 being most pronounced. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL20301
24 Samples

Download data: TXT

Series

Accession:: GSE144759

ID:: 200144759

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20012853017.

Targeting the scaffolding role of LSD1(KDM1A) poises acute myeloid leukemia cells for Retinoic Acid induced differentiation

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL11154 GPL9115
34 Samples

Download data: BED

Series

Accession:: GSE128530

ID:: 200128530

PubMed Full text in PMC Similar studies

Select item 20012852918.

Targeting the scaffolding role of LSD1(KDM1A) poises acute myeloid leukemia cells for Retinoic Acid induced differentiation [RNA-seq]

(Submitter supplied) The histone demethylase LSD1 is deregulated in several tumors, including leukemias, providing the rationale for the clinical use of LSD1 inhibitors . In acute promyelocytic leukemia (APL), pharmacological doses of retinoic acid (RA) induce differentiation of APL cells through degradation of the PML-RAR oncogene. APL cells are resistant to LSD1 inhibition or knock-out, but LSD1 inhibition sensitizes them to physiological doses of RA without altering the stability of PML-RAR, and extends survival of leukemic mice upon RA treatment. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platforms:: GPL9115 GPL11154
9 Samples

Download data: TXT

Series

Accession:: GSE128529

ID:: 200128529

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20012852819.

Targeting the scaffolding role of LSD1(KDM1A) poises acute myeloid leukemia cells for Retinoic Acid induced differentiation [ChIP-seq]

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL11154 GPL9115
25 Samples

Download data: BED

Series

Accession:: GSE128528

ID:: 200128528

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20014541020.

Single-cell RNA-seq of AML patient bone marrow treated with INCB059872, azacitidine, or combination

(Submitter supplied) INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. We evaluated a pre-treatment bone marrow sample of a patient who showed a clinical response to INCB059872 + azacitidine treatment. Single-cell RNA-sequencing (scRNA-seq) showed that INCB059872 caused a shift in gene expression that was associated with GFI1/GFI1B regulation.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
8 Samples

Download data: MTX, TSV

Series

Accession:: GSE145410

ID:: 200145410

PubMed Full text in PMC Similar studies SRA Run Selector

GEO DataSets

Functional Genomics Studies

Result Filters

Entry type

Organism

Study type

Author

Attribute name

Publication dates

Custom date range

Additional filters

Send to:

Links from GEO DataSets

Items: 20

Send to:

Supplemental Content

Find related data

Important Links

Recent activity